Trial Profile

SHR-1210, a Novel Anti-PD-1 Antibody, in Combination With Apatinib and Irinotecan/Paclitaxel Liposome Plus Nedaplatin in Patients With Previously Untreated Advanced or Metastatic Esophageal Squamous Cell Cancer: a Phase II Study

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 27 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camrelizumab (Primary) ; Irinotecan (Primary) ; Nedaplatin (Primary) ; Paclitaxel (Primary) ; Rivoceranib (Primary)
Indications Oesophageal cancer; Squamous cell cancer
Focus Therapeutic Use

09 Feb 2020 Planned number of patients changed from 30 to 45.
04 Jun 2019 Results (n=29) assessing efficacy of camrelizumab plus apatinib in combination with liposomal paclitaxel and nedaplatin advanced esophageal squamous cell carcinoma, presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
03 Aug 2018 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com